SCHEMBL3277119

SCHEMBL3277119

Cn1c(Cl)ccc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.41
HSD17B10 Q99714 5/20 0.38
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 4/20 0.38
HPGD P15428 3/20 0.38
GPR35 Q9HC97 1/20 0.37
RHEB Q15382 1/20 0.36
POLB P06746 2/20 0.36
APEX1 P27695 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C9 P11712 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
GFER P55789 1/20 0.35
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
NPC1 O15118 1/20 0.33
GRN P28799 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL71983 0.83 MCL1 (0.48) MCL1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL17296431 0.82 ALDH1A1 (0.33) ALDH1A1HPGDPOLBSMN1; SMN2MEN1
SCHEMBL1663159 0.74 NAMPT (0.44) MCL1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL5172834 0.74 MCL1 (0.42) MCL1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL10434513 0.74 HDAC4 (0.47) ALDH1A1RHEBSMN1; SMN2ALOX15TSHR
SCHEMBL11091486 0.73 PTGS1 (0.33) HSD17B10ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL5172868 0.73 MCL1 (0.41) MCL1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL1529724 0.73 MCL1 (0.46) MCL1HSD17B10ALDH1A1KDM4EHPGD
SCHEMBL10945105 0.72 SRD5A2 (0.55) HPGDPOLBCYP2C9MEN1KMT2A
SCHEMBL1665098 0.72 ALDH1A1 (0.38) MCL1HSD17B10ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1877365-B1 ACETYLENE DERIVATIVES NOVARTIS AG (CH) 2010-11-10 EP claimed
EP-1877365-B1 ACETYLENE DERIVATIVES NOVARTIS AG (CH) 2010-11-10 EP disclosed
US-20100099682-A1 ACETYLENE DERIVATIVES NOVARTIS AG 2010-04-22 US disclosed
US-7696379-B2 Acetylene derivatives NOVARTIS AG (CH) 2010-04-13 US disclosed
WO-2010000763-A2 COMBINATION PRODUCTS NOVARTIS AG (CH) 2010-01-07 WO disclosed
US-20080214673-A1 Acetylene Derivatives NOVARTIS AG (CH) 2008-09-04 US disclosed
EP-1877365-A1 ACETYLENE DERIVATIVES Novartis AG (CH) 2008-01-16 EP disclosed
WO-2006114262-A1 ACETYLENE DERIVATIVES NOVARTIS AG (CH) 2006-11-02 WO disclosed
EP-0695748-B1 Tetrazolinone herbicides BAYER AGROCHEM KK (JP) 1999-05-06 EP disclosed
US-5589439-A HERBICIDES NIHON BAYER AGROCHEM K.K. (JP) 1996-12-31 US disclosed
EP-0695748-A1 Tetrazolinone herbicides NIHON BAYER AGROCHEM K.K. (JP) 1996-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099682-A1 ACETYLENE DERIVATIVES NAT1, NAT10, F12 MCL1 2235/4885HSD17B10 154/4885ALDH1A1 69/4885
US-20080214673-A1 Acetylene Derivatives NAT1, NAT10, F12 MCL1 2235/4885HSD17B10 154/4885ALDH1A1 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.